SCHEMBL348252

SCHEMBL348252

COC(=O)c1ccc2c(Br)nn(-c3ccc(C)cc3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
ESR1 P03372 1/20 0.41
DGAT2 Q96PD7 1/20 0.41
KDM4A O75164 1/20 0.40
MAPT P10636 5/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 5/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
AHR P35869 1/20 0.39
HPGD P15428 2/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347794 0.90 TDP1 (0.46) TDP1KDM4AMAPTKDM4EGAA
SCHEMBL20166406 0.89 DGAT2 (0.47) DGAT2
SCHEMBL347407 0.82 ELANE (0.45) DGAT2MAPTKDM4EGAAALDH1A1
SCHEMBL7426182 0.79 ALDH1A1 (0.43) MAPTKDM4EGAAALDH1A1KMT2A
SCHEMBL29950049 0.79 ALDH1A1 (0.43) MAPTKDM4EGAAALDH1A1KMT2A
SCHEMBL347021 0.78 DGAT2 (0.54) ESR1DGAT2
SCHEMBL346584 0.78 DGAT2 (0.65) DGAT2
SCHEMBL347829 0.75 KDM4E (0.42) DGAT2MAPTKDM4EGAAALDH1A1
SCHEMBL31632866 0.74 NOTUM (0.42) MAPTKDM4EGAAALDH1A1KMT2A
SCHEMBL347030 0.74 TDP1 (0.49) TDP1KDM4AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411001-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2018-01-17 EP disclosed
US-8569512-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2013-10-29 US disclosed
EP-2411001-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
US-20120015052-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2012-01-19 US disclosed
WO-2010111060-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015052-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 TDP1 1765/4885ESR1 1559/4885DGAT2 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.